AbbVie (NYSE:ABBV) Announces Q4 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its fourth quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.830-3.870 for the period, compared to the consensus earnings per share estimate of 3.890. The company issued revenue guidance of $18.4 billion, compared to the consensus revenue estimate of $18.3 billion. AbbVie also updated its FY 2026 guidance to 13.950-13.990 EPS.

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Citigroup lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Morgan Stanley raised their target price on shares of AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a research note on Monday. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Finally, Guggenheim lifted their price target on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $297.46.

AbbVie Trading Up 2.9%

ABBV stock opened at $294.15 on Thursday. AbbVie has a 1-year low of $190.75 and a 1-year high of $298.74. The business’s 50 day simple moving average is $270.80 and its 200 day simple moving average is $238.28. The firm has a market capitalization of $519.71 billion, a PE ratio of 50.63, a PEG ratio of 1.30 and a beta of 0.20.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter last year, the firm posted $1.86 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts predict that AbbVie will post 13.99 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is 125.30%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie beat third-quarter earnings and revenue expectations, reporting $17.4 billion in revenue, and raised its 2026 adjusted EPS outlook to $13.95–$13.99 and revenue guidance to $67.8 billion. The results support the company’s growth case. AbbVie Stock Climbs As Q3 Earnings Fuel Growth Case
• Positive Sentiment: AbbVie licensed global rights to Nxera Pharma’s experimental oral IBD drug NXE0033744, paying $100 million upfront and offering up to $1.37 billion in development and commercial milestones, plus royalties. The candidate could broaden AbbVie’s IBD pipeline, although it remains experimental. AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
• Positive Sentiment: AbbVie expanded its Oxford research facility as part of an investment exceeding £120 million, bolstering UK R&D capacity in immunology, neurology and oncology. AbbVie expands Oxford R&D facility
• Positive Sentiment: Several analysts raised price targets or expressed optimism following the earnings report, adding to favorable sentiment around the results. Morgan Stanley raises AbbVie price target
• Neutral Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 was below the cited $3.89 consensus, while revenue guidance of $18.4 billion was above expectations—an uneven near-term outlook. AbbVie Q3 earnings and outlook
• Negative Sentiment: AbbVie discontinued a Phase 2 solid-tumor drug program after seeing limited benefit, a setback for that portion of its pipeline. The stock’s already strong run and high valuation may also leave less room for disappointment. AbbVie abandons Phase 2 solid tumor drug

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.